ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Rated “Moderate Buy” by Wall Street Brokerages

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) have been given a consensus recommendation of “Moderate Buy” by the eight research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $7.60.

A number of analysts recently issued reports on the company. Bank of America started coverage on ProQR Therapeutics in a report on Thursday, August 20th. They issued a “buy” rating and a $8.00 price target for the company. Wall Street Zen raised shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, August 15th. Citigroup reiterated a “market outperform” rating on shares of ProQR Therapeutics in a research report on Thursday, October 1st. Chardan Capital reissued a “buy” rating and issued a $3.00 price objective on shares of ProQR Therapeutics in a report on Thursday, October 1st. Finally, Weiss Ratings raised shares of ProQR Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 14th.

Institutional Investors Weigh In On ProQR Therapeutics

A number of hedge funds have recently modified their holdings of PRQR. Bank of America Corp DE raised its stake in shares of ProQR Therapeutics by 6.4% in the 1st quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company’s stock valued at $300,000 after acquiring an additional 11,186 shares during the period. Walleye Capital LLC boosted its holdings in ProQR Therapeutics by 2.7% in the 1st quarter. Walleye Capital LLC now owns 607,529 shares of the biopharmaceutical company’s stock valued at $984,000 after purchasing an additional 15,744 shares in the last quarter. Axiom Investment Management LLC acquired a new stake in shares of ProQR Therapeutics in the first quarter valued at about $53,000. Finally, RFG Advisory LLC increased its stake in ProQR Therapeutics by 236.8% in the 2nd quarter. RFG Advisory LLC now owns 64,000 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 45,000 shares in the last quarter. Hedge funds and other institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Stock Performance

Shares of PRQR opened at $1.29 on Friday. The stock has a market capitalization of $135.91 million, a PE ratio of -2.80 and a beta of 0.20. The company’s fifty day moving average is $1.83 and its 200 day moving average is $1.74. ProQR Therapeutics has a fifty-two week low of $1.24 and a fifty-two week high of $3.00.

ProQR Therapeutics (NASDAQ:PRQR) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.04. ProQR Therapeutics had a negative net margin of 223.51% and a negative return on equity of 73.83%. The business had revenue of $10.00 million for the quarter, compared to the consensus estimate of $4.56 million. As a group, research analysts forecast that ProQR Therapeutics will post -0.45 earnings per share for the current year.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a biotechnology company focused on developing RNA therapies for genetic diseases. The company uses its Axiomer RNA-editing platform to investigate treatments designed to correct disease-causing genetic changes at the RNA level without permanently altering DNA.

ProQR’s research has included therapies for rare inherited disorders, particularly genetic diseases affecting the eye and nervous system. Its development programs have included investigational treatments for inherited retinal diseases, while the company has also pursued partnerships and licensing opportunities to advance RNA-editing applications across additional disease areas.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR serves the global biotechnology and pharmaceutical markets through its research, development and strategic collaborations.